Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 99.55% is 131% above its 5-year average of -320.62%, near the high end of its 5-year range (-37344.76%–100.00%).
93.24% above its 12-month average of 51.52%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
99.55%
GROSS MARGIN AVG TTM
51.52%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
-320.62%
GROSS MARGIN AVG 10Y
-319.01%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+93.24%
CURRENT VS 3Y AVG
-0.45%
CURRENT VS 5Y AVG
+131.05%
CURRENT VS 10Y AVG
+131.21%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+140.58%
vs the sector median at left
Viridian Therapeutics, Inc.
Market Cap
$2.06B
Gross Margin
99.55%
TTM Avg
51.52%
3Y Avg
100.00%
5Y Avg
-320.62%
Market Cap
$2.06B
Gross Margin
100.00%
TTM Avg
-1064.88%
3Y Avg
-1783.56%
5Y Avg
-1442.31%
Market Cap
$2.05B
Gross Margin
74.56%
TTM Avg
73.48%
3Y Avg
70.60%
5Y Avg
69.69%
Market Cap
$2.02B
Gross Margin
97.82%
TTM Avg
97.53%
3Y Avg
97.80%
5Y Avg
96.20%
Market Cap
$2.11B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
22.50%
5Y Avg
47.90%
Market Cap
$2.02B
Gross Margin
90.85%
TTM Avg
89.42%
3Y Avg
88.91%
5Y Avg
89.39%
Market Cap
$2.02B
Gross Margin
90.36%
TTM Avg
88.22%
3Y Avg
91.04%
5Y Avg
93.63%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | 99.55% | 51.52% | 100.00% | -320.62% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | 100.00% | -1064.88% | -1783.56% | -1442.31% |
| Alvotech (ALVO)vs › | $2.08B | 60.45% | 60.99% | 17.21% | 44.81% |
| Vericel Corporation (VCEL)vs › | $2.05B | 74.56% | 73.48% | 70.60% | 69.69% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 24.57% | 22.67% | 22.13% | 21.88% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 97.82% | 97.53% | 97.80% | 96.20% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | 0.00% | 0.00% | 22.50% | 47.90% |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | 90.85% | 89.42% | 88.91% | 89.39% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 90.36% | 88.22% | 91.04% | 93.63% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
99.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | -142.42% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | -37344.76% |
| 2022-09-30 | -1750.96% |
| 2022-06-30 | -8381.25% |
| 2022-03-31 | -8115.74% |
| 2021-12-31 | -10364.49% |
| 2021-09-30 | -3804.33% |
| 2021-06-30 | -1052.75% |
| 2021-03-31 | -851.48% |
| 2020-12-31 | -28148.15% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | -629.20% |
| 2019-09-30 | -1198.85% |
| 2019-06-30 | -242.04% |
| 2019-03-31 | -2252.42% |
| 2018-12-31 | -1629.83% |
| 2018-09-30 | -683.79% |
| 2018-06-30 | -283.82% |
| 2018-03-31 | -34.05% |
| 2017-12-31 | -319.30% |
| 2017-09-30 | -207.66% |
| 2017-06-30 | -664.21% |
| 2017-03-31 | -791.77% |
| 2016-12-31 | 8.47% |
| 2016-09-30 | 32.62% |
| 2016-06-30 | 28.15% |
| 2016-03-31 | 23.11% |
| 2015-12-31 | 30.80% |
| 2015-09-30 | -15.17% |
| 2015-06-30 | 7.63% |
| 2015-03-31 | -17.83% |
| 2014-12-31 | -39.00% |
| 2014-09-30 | 33.01% |
| 2014-06-30 | 46.94% |
| 2014-03-31 | 39.18% |
| 2013-12-31 | 64.37% |
| 2013-09-30 | 27.49% |
| 2013-06-30 | 45.32% |
| 2013-03-31 | 41.29% |
